TRMT1

Across TCGA pan-cancer cohorts, TRMT1 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of TRMT1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TRMT1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TRMT1 is over-expressed in tumor.

KIRC, COAD, and KIRP are the cancer types where TRMT1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRMT1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+0.902	<.001	12	view →
COAD	All	IV	+1.825	<.001	11	view →
KIRP	All	II,III,IV	+1.144	<.001	11	view →
LIHC	Female	II,III,IV	+1.644	<.001	9	view →
STAD	Male	II,III,IV	+1.283	<.001	9	view →
HNSC	Male	IV	+0.995	<.001	8	view →
LUSC	Male	II,III,IV	+1.049	<.001	7	view →
BLCA	All	All	+0.592	<.001	6	view →
LUAD	Female	All	+0.479	<.001	6	view →
CHOL	Female	All	+2.570	<.001	5	view →
READ	Female	All	+1.512	<.001	5	view →
THCA	All	All	+0.263	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

TRMT1–KIRC

Open the KIRC breakdown →